

1 **Viral Variants and Vaccinations: If We Can Change** 2 **the COVID-19 Vaccine... Should We?**

3
4 **Sharon Bewick¹**

5 ¹Department of Biological Sciences, Clemson University, Clemson, South Carolina, U.S.A

6 7 **Abstract**

8 As we close in on one year since the COVID-19 pandemic began, hope has been placed on
9 bringing the virus under control through mass administration of recently developed vaccines.
10 Unfortunately, newly emerged, fast-spreading strains of COVID-19 threaten to undermine
11 progress by interfering with vaccine efficacy. While a long-term solution to this challenge would
12 be to develop vaccines that simultaneously target multiple different COVID-19 variants, this
13 approach faces both developmental and regulatory hurdles. A simpler option would be to switch
14 the target of the current vaccine to better match the newest viral variant. I use a stochastic
15 simulation to determine when it is better to target a newly emerged viral variant and when it is
16 better to target the dominant but potentially less transmissible strain. My simulation results
17 suggest that it is almost always better to target the faster spreading strain, even when the initial
18 prevalence of this variant is much lower. In scenarios where targeting the slower spreading
19 variant is best, all vaccination strategies perform relatively well, meaning that the choice of
20 vaccination strategy has a small effect on public health outcomes. In scenarios where targeting
21 the faster spreading variant is best, use of vaccines against the faster spreading viral variant can
22 save many lives. My results provide ‘rule of thumb’ guidance for those making critical decisions
23 about vaccine formulation over the coming months.

24

25 **Introduction**

26 On March 11, 2020, the World Health Organization (WHO) declared the COVID-19
27 outbreak a global pandemic¹. Since then, much effort has focused on developing safe and
28 effective vaccines that can bring the world back to normality². Remarkably, exactly 9 months
29 after the WHO declared a global pandemic, the U.S. Food and Drug Administration (FDA)
30 announced an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19
31 vaccine³ – the first vaccine against COVID-19 to receive approval in the United States.
32 Additional authorizations have followed rapidly. For instance, an EUA was issued for the
33 Moderna COVID-19 vaccine a mere one week after the EUA for the Pfizer-BioNTech vaccine⁴.
34 Notably, this timeline for vaccine development and approval is over four times faster than any
35 previous vaccine efforts⁵. Further, initial clinical trials suggest that these early vaccines against
36 COVID-19 are highly effective, with both Pfizer-BioNTech and Moderna reporting efficacies
37 exceeding 90%^{6,7}, which is comparable to some of the best vaccines currently in use.

38 In large part, the remarkable speed with which the world has developed safe, efficacious
39 COVID-19 vaccines is a result of years of advances in molecular biology. Indeed, both the
40 Pfizer-BioNTech vaccine and the Moderna vaccine rely on a novel messenger RNA (mRNA)
41 approach^{8,9} for stimulating the immune system. Though there are some drawbacks of mRNA
42 vaccines – most notably the requirement for cold-chain storage – this technology greatly
43 facilitates rapid and targeted vaccine development based solely on the genetic sequence of the
44 virus¹⁰. This, in turn, allows vaccine candidates to be made without ever needing to culture the
45 virus itself. Another related advantage of mRNA vaccines is their flexibility. In particular,
46 because their only requirement is the genetic code for a particular antigenic component of the
47 target virus, it is not difficult to alter these vaccines in response to strain variation.

48 In early December 2020, the United Kingdom reported a novel and potentially
49 concerning COVID-19 variant, B.1.1.7^{11,12}. What is particularly troublesome about this variant is
50 that it has a large number of mutations – 23 in total, 17 of which are non-silent¹². Further, 8 of
51 these mutations occur in the spike protein, which is the portion of the virus responsible for
52 enabling viral entry into human cells¹². These novel mutations include the N501Y mutation that
53 allows the virus to bind more tightly to the human angiotensin converting enzyme 2 (ACE2)
54 receptor¹³, as well as the D614G deletion that appears to make the virus more transmissible
55 between individuals¹⁴. Substantial genetic changes, along with accelerating rates of spread, and a
56 rapid rise to dominance of the B.1.1.7 variant in Southern England¹⁵, suggest that the B.1.1.7 has
57 a fitness advantage. In fact, recent modeling studies indicate that the B.1.1.7 variant could be 50-
58 70% more transmissible than previous COVID-19 strains^{11,16}.

59 Beyond altered transmissibility, another threat of the B.1.1.7 mutant is that existing
60 vaccines may be less effective against it. This is because most vaccines in development
61 specifically target the viral spike protein². Currently Pfizer-BioNTech and Moderna are
62 conducting in vitro assays that will provide first estimates of the efficacy of existing vaccines
63 against the novel B.1.1.7 COVID-19 variant. Full assessment of vaccine efficacy will follow in a
64 matter of weeks to months, as existing vaccines are rolled-out in locations like Southern England
65 where the B.1.1.7 variant is dominant. However, even if current vaccines are efficacious against
66 B.1.1.7, the emergence of this viral variant is a warning call. In particular, we can expect
67 COVID-19 to continue to mutate and to generate novel variants that differ from the initial
68 vaccine targets. The obvious long-term solution is to develop vaccines that contain DNA from all
69 of the dominant COVID-19 variants in circulation (multivalent), much like the seasonal
70 influenza vaccine¹⁷. However, because mRNA vaccine technology is new, multivalent COVID-

71 19 mRNA vaccines have not been tested. Thus, it is unclear whether presenting multiple
72 antigenic components through mixed mRNAs will actually provide even immune coverage to all
73 components, or whether there will be interference effects¹⁸. Likewise, it is unclear whether there
74 are any additional health risks to mixed mRNA vaccines. As a consequence, multivalent
75 COVID-19 vaccines pose both development and regulatory hurdles. A simpler approach to
76 combat COVID-19 strain evolution is to ‘switch out’ the viral mRNA in the existing single strain
77 (monovalent) vaccine in response to changes in the dominance of the circulating strains.
78 Currently, for example, that could mean switching to the mRNA for the spike protein from the
79 B.1.1.7 viral variant.

80 While it may seem obvious that COVID-19 vaccines should be altered to track the
81 dominant viral strains in circulation, there are costs involved with switching. Further, without
82 sufficient cross-protection, vaccination against one viral variant will cause the other to rise to
83 dominance and vice versa, essentially leading to a game of whack-a-mole. While this scenario
84 cannot be avoided entirely, there may still be better and worse decisions in terms of the viral
85 variant that is selected for vaccine efforts. This is because not all viral variants are biologically
86 equivalent. Some viral variants, like B.1.1.7 are more transmissible. Others may be more
87 prevalent, or may have already swept a larger fraction of the population, at least at the time of the
88 initial vaccine roll-out. This, then, begs the question: When multiple COVID-19 viral variants
89 are circulating, and when vaccine cross-protection is not complete, which variant should be
90 targeted for vaccine scale-up during the initial vaccination phase?

91 In this paper, I use a simple stochastic simulation to examine the outcomes of various
92 vaccine strategies against two different co-circulating COVID-19 viral variants. In particular, I
93 examine how the best choice of vaccine target depends on the degree of cross-protection offered

94 by vaccination and/or natural immunity to the alternate strain. I also consider how outcomes
95 depend on the relative transmissibilities of the different viral variants, their relative prevalence at
96 the beginning of the vaccination period, and existing natural immunity. Finally, I consider how
97 differences in the timing of vaccine roll-out can change predictions, and what this might mean as
98 we rapidly scale-up a series of different mRNA vaccines against the COVID-19 pandemic.

99

100 **Method**

101 I use the Gillespie algorithm (GA)¹⁹— a discrete-time, event-based simulation approach — to study
102 transmission of two different COVID-19 viral variants in a human population undergoing rapid
103 roll-out of a COVID-19 vaccine that is targeted at only one of the two variants (monovalent). For
104 each individual in the population, I assume that they can be in one of four potential infection
105 classes, one of four potential natural immunity classes and one of four potential vaccination
106 classes. Specifically, individuals can be: virus-free ($i = 0$), infected with the first viral variant ($i =$
107 1), infected with the second viral variant ($i = 2$) or infected with both viral variants ($i = 3$).
108 Likewise, individuals can be: fully naturally susceptible ($j = 0$), naturally immune to the first
109 viral variant ($j = 1$), naturally immune to the second viral variant ($j = 2$) or naturally immune to
110 both viral variants ($j = 3$). Finally, individuals can be: unvaccinated ($k = 0$), vaccinated against
111 the first viral variant ($k = 1$), vaccinated against the second viral variant ($k = 2$) or vaccinated
112 against both viral variants ($k = 3$). Ultimately, this leads to $4 \times 4 \times 4 = 64$ possible states for each
113 individual. I then define a matrix, N , where each element, $N_{i,j,k}$, specifies the number of
114 individuals in the i^{th} infection class, the j^{th} natural immunity class and the k^{th} vaccination class.
115 Depending on model assumptions, not all states may be possible, in which case $N_{i,j,k} = 0$ (e.g., if
116 there are no double vaccinations, then $N_{i,j,3} = 0$).

117 *Viral Transmission*

118 I assume frequency-dependent viral transmission. Thus, the probability of a new viral infection
 119 involving viral variant i is proportional to both the number of individuals infected with that
 120 variant and the number of individuals susceptible to that variant, and is inversely proportional to
 121 total population size. I assume that natural immunity and/or vaccine-induced immunity impact
 122 the probability of transmission of each viral variant, but are not necessarily fully protective, even
 123 against the ‘on-target’ viral variant. Specifically

$$\begin{aligned}
 124 \quad & P_T(N_{i,j,k,t+\Delta t} = n + 1, N_{\gamma,j,k,t+\Delta t} = m - 1 \mid N_{i,j,k,t} = n, N_{\gamma,j,k,t} = m) \\
 125 \quad & = \begin{cases} \frac{\beta_i (1 - \max(\varepsilon_{ji}, v_{ki})) N_{\gamma,j,k} \sum_{j,\hat{k}} (N_{i,j,\hat{k}} + N_{3,j,\hat{k}}) \Delta t}{\sum_{i,j,\hat{k}} N_{i,j,\hat{k}}} & i = 1,2, \gamma = 0 \\ \frac{\beta_{\gamma'} (1 - \max(\varepsilon_{j\gamma'}, v_{k\gamma'})) N_{\gamma,j,k} \sum_{j,\hat{k}} (N_{\gamma',j,\hat{k}} + N_{3,j,\hat{k}}) \Delta t}{\sum_{i,j,\hat{k}} N_{i,j,\hat{k}}} & i = 3, \gamma = 1,2 \\ 0 & \text{otherwise} \end{cases} \\
 126 \quad & \hspace{20em} (1)
 \end{aligned}$$

127 where $P_T(N_{i,j,k,t+\Delta t} = n + 1, N_{\gamma,j,k,t+\Delta t} = m - 1 \mid N_{i,j,k,t} = n, N_{\gamma,j,k,t} = m)$ is the probability of

128 an individual transferring from the γ infection class to the i infection class and $\gamma' = \begin{cases} 1 & \gamma = 2 \\ 2 & \gamma = 1 \end{cases}$.

129 In equation (1), β_i is a parameter that describes the transmissibility of viral variant i , ε_{ji} is a
 130 parameter that describes the reduction in transmission of viral variant i to an individual of
 131 immunity state j and v_{ki} is a parameter that describes the reduction in transmission of viral
 132 variant i to an individual of vaccination state k . For all models that I consider, I assume that $\varepsilon_{ji} =$
 133 v_{ki} when $j = k$ (natural immunity and vaccine induced immunity confer similar levels of
 134 protection). Further, I assume that $\varepsilon_{11} = \varepsilon_{22} = v_{11} = v_{22}$ and that $\varepsilon_{12} = \varepsilon_{21} = v_{12} = v_{21}$ (both
 135 viral variants perform similarly in terms of the degree of conferred same-strain protection and the
 136 degree of conferred cross-strain protection). Notice that equation (1) makes several simplifying

137 assumptions. First, a current infection with one viral variant does not impact the likelihood of a
 138 secondary infection with the alternate viral variant. Second, co-infected individuals spread each
 139 viral variant at the same rate as if they were singly infected. Third, immunity and vaccination
 140 status do not impact the extent to which an infected individual spreads disease. Fourth, co-
 141 infections are picked up serially, rather than as a result of direct transfer from a co-infected
 142 individual. All of these assumptions could be relaxed, though with the requirement for
 143 additional parameters.

144

145 *Recovery*

146 I assume a constant probability of recovery of infected individuals. Further, I assume that, upon
 147 recovery, an individual acquires natural immunity to the viral variant that they were infected
 148 with (or remains naturally immune, if they already had immunity to that particular strain). Thus,

149
$$P_R(N_{0,\gamma,k,t+\Delta t} = n + 1, N_{i,j,k,t+\Delta t} = m - 1 | N_{0,\gamma,k,t} = n, N_{i,j,k,t} = m) =$$

 150
$$\begin{cases} r_{i,j,k} N_{i,j,k} \Delta t & i > 0, j = 0, i, \gamma = i \text{ OR } i > 0, j = 1, 2, i \neq j, \gamma = 3 \\ 0 & \text{otherwise} \end{cases}$$

151 (2)

152 where $P_R(N_{0,i,k,t+\Delta t} = n + 1, N_{i,j,k,t+\Delta t} = m - 1 | N_{0,i,k,t} = n, N_{i,j,k,t} = m)$ is the probability of
 153 an individual transitioning from the i infection class to the virus-free infection class ($i = 0$) and
 154 the γ immunity class. In equation (2), the rate of recovery can depend on the viral variant, on
 155 whether an individual is infected with a single viral variant or is co-infected, and on the
 156 immunity and vaccination status of the infected individual. However, in all models that I
 157 consider, I assume $r_{i,j,k} = r$; thus all individuals have similar probabilities of recovery,
 158 regardless of disease state or immunity status.

159

160 *Death*

161 I assume a constant probability of death of infected individuals and do not consider additional
 162 death or birth in the population. Specifically

$$163 \quad P_D(N_{i,j,k,t+\Delta t} = n - 1 | N_{i,j,k,t} = n) = \begin{cases} \mu_{i,j,k} N_{i,j,k} & i > 0 \\ 0 & \text{otherwise} \end{cases} \quad (3)$$

164 where $P_D(N_{i,j,k,t+\Delta t} = n - 1 | N_{i,j,k,t} = n)$ is the probability of an individual from the i infection
 165 class being removed from the population. In equation (3), the probability of dying depends on
 166 the particular viral infection, as well as the immunity status of the host. However, as with
 167 recovery, for all models that I consider, I assume that $\mu_{i,j,k} = \mu_i$. This means that death rate is
 168 only a function of the viral variant(s) causing the infection but does not depend on immune status
 169 of the host.

170

171 *Vaccination*

172 I assume a constant probability of vaccination, and that vaccination does not take into account
 173 the natural immunity status or infection status of the individual. I make this assumption given the
 174 large number of asymptomatic infections that make it difficult to know whether a person has
 175 been previously infected or, indeed, even whether a person is currently infected. I do, however,
 176 assume that people who have already been vaccinated are not re-vaccinated. Finally, I assume
 177 that vaccination proceeds at a fixed rate until all individuals willing to receive a vaccine have
 178 done so. Once all willing individuals have been vaccinated, vaccination stops. Thus

$$179 \quad P_V(N_{i,j,\kappa,t+\Delta t} = n + 1, N_{i,j,k,t+\Delta t} = m - 1 | N_{i,j,\kappa,t} = n, N_{i,j,k,t} = m) =$$

$$180 \quad \begin{cases} \omega_\kappa & k = 0, \kappa = 1, 2, \sum_{\hat{i}, \hat{j}, \hat{k}=1,2} N_{\hat{i}, \hat{j}, \hat{k}} / \sum_{\hat{i}, \hat{j}, \hat{k}} N_{\hat{i}, \hat{j}, \hat{k}} < \theta \\ 0 & \text{otherwise} \end{cases} \quad (4)$$

181 where $P_V(N_{i,j,\kappa,t+\Delta t} = n + 1, N_{i,j,k,t+\Delta t} = m - 1 | N_{i,j,\kappa,t} = n, N_{i,j,k,t} = m)$ is the probability of
182 an individual with vaccination status k receiving the vaccine and transitioning to vaccination
183 status κ , ω_κ is the rate at which the vaccine is administered and θ is the fraction of the
184 population willing to receive a vaccine.

185

186 *Parameters and Initial Conditions*

187 Except where noted otherwise, I assume the parameter values as outlined in Table 1. Briefly, I
188 assume that both vaccines and natural immunity are 95% effective at preventing infection when
189 targeted at the same viral variant. This is commensurate with early reports from both Pfizer-
190 BioNTech and Moderna^{6,7}, as well as low reports of re-infection across the world. Likewise, I
191 assume that a person who has been infected can spread the virus for 10 days²⁰ (notice that it does
192 not matter whether the person has symptoms for any or all of this period). I assume that the death
193 rate due to disease is 0.0006/day which, for a 10 day infection period, leads to a 0.6% death rate,
194 again commensurate with current reports on COVID-19 infection fatality ratios (IFRs)²¹. Finally,
195 I assume that a person infected with the original COVID-19 variant spreads the disease to, on
196 average, 2 additional people²², while a person infected with the new viral variant spreads the
197 disease to, on average, 3 additional people (i.e., 50% more infectious). Finally, I assume that
198 100% of the population is willing to/forced to receive the vaccine, and that 5000 people per day,
199 can be vaccinated in a 500,000 person population (i.e., it takes 100 days or approximately 3
200 months to vaccinate the entire focal population).

201 For initial conditions, I assume that, at the start of the simulation, a pre-defined fraction
202 of the population, ρ_1 , is infected with the first viral variant, and a pre-defined fraction of the
203 population, ρ_2 , is infected with the second viral variant. I ignore co-infections at the beginning of

204 the simulation under the assumption that $\rho_1 \rho_2 \sum_{i,j,\hat{k}} N_{i,j,\hat{k}} \ll 1$ for reasonably small ρ_1 and/or ρ_2 .
 205 Likewise, I assume that, at the start of the simulation, a pre-defined fraction of the population,
 206 φ_1 , is immune as a result of previous infection with the first viral variant, and that a pre-defined
 207 fraction of the population, φ_2 , is immune as a result of previous infection with the second viral
 208 variant. As with infection, I assume that there are no individuals who have acquired natural
 209 immunity to both viruses, which is a good approximation when either φ_1 or φ_2 are small (at least
 210 one strain has not been circulating for a long time) or when ε_{12} or ε_{21} are large (natural cross-
 211 protection is high, making serial infection with different strains less likely). In practice, most
 212 simulations that I consider assume that the second COVID-19 strain is a recent introduction, and
 213 thus $\varphi_2 \sim 0$.

214 **Table 1:** Parameters and initial conditions used in simulations

Parameter	Symbol	Value
Natural immunity against same variant	$\varepsilon_{11}, \varepsilon_{22}$	0.95 ^{6,7}
Natural cross-protection against the opposite variant	$\varepsilon_{12}, \varepsilon_{21}$	0.70
Vaccine induced immunity against same variant	v_{11}, v_{22}	0.95
Vaccine induced cross-protection against the opposite variant	v_{12}, v_{21}	0.70
Recovery rate	r	0.1 ²⁰
Death rate	μ_1, μ_2	0.0006 ²¹
Transmission rate of COVID-19 variant 1	β_1	0.2 ²²
Transmission rate of COVID-19 variant 2	β_2	0.3
Fraction of population willing to receive vaccine	θ	1
Vaccination rate	$\omega_1 + \omega_2$	5000
Population size	$\sum_{i,j,\hat{k}} N_{i,j,\hat{k}}$	500000
Initial fraction infected with variant 1	ρ_1	0.001
Initial fraction infected with variant 2	ρ_2	0.00001
Initial fraction naturally immune to variant 1	φ_1	0.10
Initial fraction naturally immune to variant 2	φ_2	0

215

216 Python code for model simulations is provided at:


217 <https://github.com/bewicklab/COVID-Vaccination-Strategies>

218 **Results**

219 In the analysis that follows, I consider three different vaccination strategies. First, I consider a
220 scenario where all doses of the vaccine are targeted against viral variant 1 (blue lines). Second, I
221 consider a scenario where all doses of the vaccine are targeted against viral variant 2 (red lines).
222 Finally, I consider a scenario where two different types of vaccines are in use, with 50% of the
223 doses targeted against viral variant 1, and 50% of the doses targeted against viral variant 2
224 (purple lines; this could be achieved, for example, if Pfizer-BioNTech and Moderna produced
225 different vaccines, each targeting the opposite viral variant). For each scenario, I consider three
226 metrics: (1) total deaths from the start of the simulation until the virus goes extinct, (2) peak
227 number of infections at any given time and (3) number of days until the virus goes extinct. Total
228 deaths provides an estimate of the costs of the different strategies in terms of human life. Total
229 deaths are also proportional to total infections, thus giving a sense of the overall scale of the viral
230 outbreak for each scenario. Peak number of infections is important, because an outbreak that has
231 a higher number of infectious individuals at any single point in time is more likely to overwhelm
232 healthcare facilities. Thus, even if the total sizes of two different outbreaks are the same, death
233 rates are likely to be lower for the outbreak with a lower peak infection rate (which typically
234 implies an outbreak that is spread over a longer period of time – note that my model assumes a
235 constant death rate, thus total deaths does not account for variation in death rate due to
236 overwhelmed medical facilities). Finally, the number of days until the virus goes extinct gives a
237 sense of the time required to reach herd immunity through a combination of natural infection and
238 vaccination. Longer times to viral extinction do not necessarily mean worse outbreaks in terms
239 of total infections and deaths, although they do imply a longer period over which masks and

240 social distancing may be required, particularly for at-risk people. For all simulations, I assume
241 that the first viral variant spreads at a slower rate (i.e., is less transmissible) than the second.

242



243

244 **Fig. 1** (A) Total number of deaths, (B) peak infections and (C) time to virus extinction as a
245 function of the degree of natural and vaccine-induced cross-protection ($v_{12} = v_{21} = \epsilon_{12} = \epsilon_{21}$)
246 assuming a vaccination strategy targeting viral variant 1 (blue, slower spreading), a vaccination
247 strategy targeting viral variant 2 (red, faster spreading) and a mixed strategy with 50% of the
248 population receiving the vaccine against viral variant 1 and 50% receiving the vaccine against
249 viral variant 2. All parameters and initial conditions except those associated with cross-
250 protection ($v_{12}, v_{21}, \epsilon_{12}, \epsilon_{21}$) are as defined in Table 1. Results shown are median values over 30
251 simulation trials.

252

253 *Degree of Cross-Protection*

254 Figure 1 shows the total number of deaths (A), peak infections (B) and time to virus extinction
255 (C) as a function of the degree of cross-protection offered by natural immunity and/or
256 vaccination to the opposite viral variant. For these simulations, I assume a total population size
257 of 500,000 individuals, and an IFR of 0.6%. Consequently, if the entire population is infected

258 with one of the two virus strains, then approximately 3000 individuals will die. Likewise, if the
259 entire population is infected with both of virus strains (simultaneously or sequentially), then
260 approximately 6000 individuals will die. Because herd immunity is typically achieved at
261 infection rates less than 100%, 3000 and 6000 deaths represent upper bounds for single
262 infections and double infections respectively. Nevertheless, these bounds help to frame
263 simulation results.

264 As expected, when cross-protection is close to zero, vaccination against one of the two
265 viral strains cuts the total death rate in half. However, it does nothing to prevent deaths from the
266 off-target viral variant. Because of this, vaccination against the more transmissible virus (in this
267 case, viral variant 2) is almost always optimal, even if the less transmissible virus is initially
268 present at substantially higher rates. This is because, regardless of initial conditions, the off-
269 target variant will inevitably sweep the population. The virus that is more transmissible,
270 however, will infect a higher proportion of the population prior to reaching herd immunity.
271 Consequently, vaccinating against this more transmissible strain is the better option when there is
272 little to no cross-protection.

273 Although faster spread of viral variant 2 is the primary factor favoring use of this strain as
274 the vaccine target at low levels of cross-protection, there are two additional advantages to
275 focusing on viral variant 2. Both are related to the fact that viral variant 1 is more prevalent.
276 While somewhat counterintuitive, higher prevalence of a particular strain prior to vaccination
277 can actually make it less effective to target that strain with the vaccine (see Fig. 5). This is
278 because higher viral prevalence goes hand-in-hand with higher levels of natural immunity, which
279 has two consequences. First, if one of the two viral variants will inevitably sweep the population
280 (i.e., low cross-protection), then it is preferable that this be the variant with more existing natural

281 immunity, since fewer additional deaths will be necessary to reach herd immunity. Second, when
282 the vaccine is targeted against the more prevalent variant, more vaccine doses are wasted
283 protecting individuals who are already naturally immune (see Figure 5). By contrast, wasted
284 vaccine doses less common when the vaccine protects against a strain without much pre-existing
285 natural immunity. Again, this disfavors use of the more prevalent strain as the vaccine target (in
286 this case, variant 1).

287 Interestingly, a relatively high level of cross-protection is required before vaccination
288 with the more prevalent but slower spreading variant becomes a competitive strategy. Increasing
289 cross-protection from 0% to 50%, for instance, only reduces total deaths by <30% when the
290 vaccine is targeted against the prevalent but slow spreading variant 1. By contrast, cross-
291 protection has a much stronger effect earlier on when the vaccine is targeted against the fast
292 spreading variant 2. In this case increasing cross-protection from 0% to 50% causes a >70%
293 reduction in deaths. Notably, even at 90% cross-protection, vaccination against the slow
294 spreading variant still underperforms in terms of preventing deaths.

295 Surprisingly, a mixed strategy, where half of the population receives the vaccine against
296 the slow spreading variant, while the other half receives the vaccine against the fast spreading
297 variant, performs almost as well as fully targeting the fast-spreading variant. This is particularly
298 notable, since a mixed strategy may be more realistic to implement, at least in the near-term, for
299 COVID-19. A mixed strategy, for example, would only require one or a few vaccine-makers to
300 alter the formulations of their vaccines. Notice, however, that my simulations assume
301 randomization of the two vaccines throughout the entire vaccine roll-out period – thus results
302 could be different if the two different vaccines were rolled out on different timelines or in
303 different spatial locations.

304 Like deaths, peak infections are also much higher under the scenario with vaccination
305 against the prevalent but slow spreading variant 1. Interestingly, however, peak infections are
306 also higher for the mixed vaccination strategy as compared to vaccination against viral variant 2,
307 at least when cross-protection <50%. This contrasts what was seen for total deaths. Nevertheless,
308 the mixed strategy still performs substantially better than vaccination against the slow spreading
309 variant 1 over most of the range of potential cross-protection levels. At high cross- protection,
310 (80-90%), differences in the different vaccination strategies are minimal, and the mixed strategy,
311 or even vaccination against the slow spreading viral variant can actually yield lower peak
312 infection levels.


313 Times to viral extinction tend to be unimodal, at least for strategies that target a single
314 viral variant. This is because, at low cross-protection, the off-target variant rapidly sweeps the
315 population, driving its own demise over a short period of time (at least in the absence of
316 introduction of newly susceptible individuals through birth or waning immunity). Meanwhile the
317 vaccine rapidly suppresses the on-target variant. Conversely, at high levels of cross-protection,
318 the vaccine itself leads to rapid extinction of both variants. At intermediate levels of cross-
319 protection, however, spread of the off-target viral variant is slowed, but not stopped, leading to
320 longer persistence of this strain in the population. While viral persistence peaks around 40%
321 cross protection for the mixed strategy and the strategy that targets the fast-spreading variant 2, it
322 peaks at a much higher 70% cross protection for the strategy that targets the slow-spreading
323 variant 1. Alarmingly, when the vaccine targets viral variant 1, the virus can persist nearly 1.5
324 years after vaccination begins, even with a rapid vaccine roll-out of 3 months.

325

326

327 *Relative Transmission Rates*

328 Figure 2 shows the total number of deaths (A), peak infections (B) and time to virus extinction
329 (C) as a function of the transmission rate of the faster spreading viral variant 2. In these
330 simulations, I assume that viral variant 1 spreads at a rate of $0.2 \text{ person}^{-1}\text{day}^{-1}$. For a typical



331
332 **Fig. 2** (A) Total number of deaths, (B) peak infections and (C) time to virus extinction as a
333 function of the transmission rate of viral variant 2 (β_2 , faster spreading) assuming a vaccination
334 strategy targeting viral variant 1 (blue, slower spreading), a vaccination strategy targeting viral
335 variant 2 (red, faster spreading) and a mixed strategy with 50% of the population receiving the
336 vaccine against viral variant 1 and the other 50% receiving the vaccine against viral variant 2.
337 All parameters and initial conditions except the transmission rate of the second viral variant (β_2)
338 are as defined in Table 1. Results shown are median values over 30 trials.
339

340 infectious period of 10 days, this means that each person, on average, spreads the virus to two
341 additional people in a fully susceptible population. This estimate is commensurate with current
342 measures of R_0 for COVID-19²². By extension, for the range of transmissibilities considered in
343 Figure 2, each person infected with viral variant 2 transmits the virus to between 2 and 4

344 additional individuals in a fully susceptible population. This is in keeping with the estimate that
345 the new B.1.1.7 COVID-19 strain is 50-70% more transmissible than its predecessor^{11,16}. Not
346 surprisingly, increasing transmissibility of the second viral variant increases overall deaths, as
347 well as peak infections at the height of the outbreak. However, the rate of increase depends on
348 vaccination strategy. When there is not much difference between the transmission rates of the
349 two viral variants, it is actually best to vaccinate against the more prevalent but slower spreading
350 viral variant 1. This is because the second viral variant is 100-fold less common at the beginning
351 of the simulation. Thus, with sufficient cross-protection ($\varepsilon_{12} = \varepsilon_{21} = 0.7$ in Figure 2), and a
352 reasonably fast vaccine roll-out (100 days), it is best to target the more prevalent strain.
353 However, the initial advantage gained by being more prevalent dissipates rapidly as the
354 transmission rate of the second viral variant increases. Thus, when the second variant spreads
355 50% faster than the first, vaccination against the second strain is marginally better (see also
356 Figure 1) and when the second variant spreads twice as fast as the first, vaccinating against the
357 faster spreading second strain dramatically reduces total deaths, as well as peak infection rates.

358 For most of the range in Figure 2, the mixed vaccination strategy is intermediate to either
359 single vaccination strategy in terms of total deaths and peak infections. However, while the
360 difference between the mixed strategy and vaccination against viral variant 2 is minimal at $\beta_2 =$
361 0.3 (see also Figure 1), this difference increases rapidly for $\beta_2 > 0.3$, such that, when the second
362 viral variant spreads twice as fast as the first, $\beta_2 = 0.4$, vaccinating against the second variant
363 save many lives, even compared to the mixed strategy. Thus, the benefits of the mixed strategy
364 seen in Figure 1 do not necessarily hold when the second viral variant is significantly more
365 transmissible. Notably, the benefit of developing vaccines against the faster spreading virus


366 emerge despite the relatively high cross-protection levels ($\varepsilon_{12} = \varepsilon_{21} = 0.7$) assumed in Figure 2
367 and despite the 100-fold greater prevalence of the first variant at the beginning of the simulation.

368 Viral times to extinction are largely independent of the transmission rate of the second
369 variant when the vaccine is targeted against this variant. This makes sense. When vaccination is
370 against the second viral variant, the final stages of the outbreak are largely determined by spread
371 of the first viral variant, meaning that the final stages of the outbreak are largely independent of
372 the properties of the second viral strain. When the vaccine in use is against the first viral variant,
373 however, the time to viral extinction is unimodal. This can be understood as follows: when the
374 second viral variant spreads slowly, it can be rapidly brought under control by cross-protection
375 from infection/vaccination against the first variant. However, rapid control through vaccination
376 is less likely when the second variant spreads more rapidly. In this case, the second variant has
377 greater potential to infect a larger fraction of the population before cross-protection, combined
378 with natural immunity, finally bring the second variant under control. For faster and faster spread
379 of the second variant, however, natural immunity occurs earlier and earlier, leading to a decrease
380 in viral time to extinction.

381

382 *Vaccine Roll-out*

383 Figure 3 shows the total number of deaths (A), peak infections (B) and time to virus extinction
384 (C) as a function of the number of people vaccinated for the virus each day. For all of the
385 simulations in Figure 3, I assume a population size of 500,000 individuals, thus it would take 100
386 days to vaccinate the entire population at a rate of 5000 people/day, and 50 days to vaccinate the
387 entire population at a rate of 10000 people/day. As expected, total deaths and peak infection rates
388 decrease sharply with increased rate of vaccination roll-out for all vaccination strategies.



389

390 **Fig. 3** (A) Total number of deaths, (B) peak infections and (C) time to virus extinction as a
391 function of vaccine roll-out rate, $\omega_1 + \omega_2$, assuming a vaccination strategy targeting viral variant
392 1 (blue, slower spreading), a vaccination strategy targeting viral variant 2 (red, faster spreading)
393 and a mixed strategy with 50% of the population receiving the vaccine against viral variant 1 and
394 the other 50% receiving the vaccine against viral variant 2. All parameters and initial conditions
395 except overall vaccination rate ($\omega_1 + \omega_2$) are as defined in Table 1. Results shown are median
396 values over 30 trials.
397

398 However, over the range from 1000-5000 people/day (i.e., 500-100 days to vaccinate the
399 population), the decrease in deaths and peak infections as a function of vaccine rollout rate is
400 greatest for vaccination against viral variant 2, intermediate for the mixed vaccination strategy
401 and slowest for vaccination against viral variant 1. Thus, not surprisingly, slower vaccine roll-
402 outs tend to favor vaccination strategies targeting the faster spreading viral variant. This is
403 because slower vaccine roll-outs leave added time for the faster spreading variant to take over,
404 even from a significant early deficit. When the vaccine roll-out is rapid (less than two months),
405 however, all three strategies perform well. In fact, the mixed strategy outperforms both single


406 vaccination strategies in terms of total deaths, and outperforms vaccination against variant 2 in
407 terms of peak infections when the entire population can be vaccinated within 100 days. Further,
408 when full vaccination can be completed within ~60 days (2 months), vaccination against the first
409 viral variant actually leads to the lowest peak infection rates, though it still gives higher total
410 deaths than the mixed vaccination strategy.

411 For both vaccination against the fast-spreading virus and the mixed vaccination strategy,
412 time to viral extinction decreases with increasing vaccine roll-out rates, commensurate with the
413 expectation that faster vaccination of the population leads to faster suppression of the virus.
414 Vaccination against the first viral variant, by contrast, leads to a peak in viral extinction times as
415 a function of vaccine roll-out rate. Again, this is a result of the trade-off between rapid
416 development of herd immunity at low roll-out rates, rapid development of vaccine-induced
417 immunity at fast roll-out rates, and a peak in the middle, where vaccination slows viral spread
418 down, but does not immediately suppress it.

419

420 *Initial Infection Rates*

421 Figure 4 shows the total number of deaths (A), peak infections (B) and time to virus extinction
422 (C) as a function of the number of people initially infected with viral variant 2. For these
423 simulations, I keep the total number of initial infections constant, thus when there are more
424 individuals infected with viral variant 2, there are fewer infected with viral variant 1. In order to
425 span a wide range of variant 1: variant 2 infection ratios while maintaining at least 5 individuals
426 infected with variant 2 (below 5 individuals, there is a sizeable likelihood of stochastic extinction
427 of the second variant), I assume a much higher baseline infection rate in Figure 4 as compared to
428



429

430 **Fig. 4** (A) Total number of deaths, (B) peak infections and (C) time to virus extinction as a
 431 function of the initial number of people in the population infected with viral variant 2,
 432 $\rho_2 \sum_{i,j,k} N$, and assuming a vaccination strategy targeting viral variant 1 (blue, slower spreading),
 433 a vaccination strategy targeting viral variant 2 (red, faster spreading) and a mixed strategy with
 434 50% of the population receiving the vaccine against viral variant 1 and the other 50% receiving
 435 the vaccine against viral variant 2. All parameters and initial conditions except initial fractions of
 436 infected individuals are as shown in Table 1. For initial fractions of infected individuals, I
 437 assume a constant total fraction, such that $(\rho_1 + \rho_2) \sum_{i,j,k} N = 5005$. Notice that this is a 10-
 438 fold higher initial infection rate than what is used in Figures 1-3. Results shown are median
 439 values over 30 trials.

440

441 Figures 1-3. Specifically, in Figure 4, I assume that 1% of individuals are COVID-19 positive at
 442 the outset of the simulation, as compared to the 0.1% infection rate that I use in Figures 1-3.


443 Despite the much higher prevalence of viral variant 1 in Figure 4, vaccinating against this
 444 variant is still generally less effective at preventing deaths. At best, vaccinating against the slow
 445 spreading viral variant 1 performs about as well as vaccinating against the fast spreading viral
 446 variant 2, and even this requires that the initial number of variant 2 infections be very low (≤ 5
 447 total variant 2 infections and a 1000:1 ratio of variant 1 to variant 2 infections in a population of

448 500,000). More commonly, however, vaccinating against the slow spreading variant 1 leads to
449 many more deaths than vaccinating against the fast spreading variant 2. While vaccinating
450 against the slow-spreading strain is a poor strategy, the mixed vaccination strategy actually
451 outperforms both single variant strategies over a wide range of infection ratios. Indeed, up to a
452 variant 1:variant 2 infection ratio of approximately 200, the mixed strategy prevents the most
453 deaths. Interestingly, although poor in terms of preventing deaths, vaccination against variant 1
454 can actually lower peak infection rates (but see Figures 1-3), suggesting that it is not necessarily
455 a poor strategy along all public health dimensions. Initial infection ratios do not have strong
456 impacts on time to virus extinction for any of the vaccine strategies considered.

457

458 *Existing Natural Immunity*

459 Because COVID-19 has been spreading in most locations since February-March 2020, many
460 people have acquired natural immunity, and this could potentially alter the benefits of the
461 different vaccination strategies. I explore this effect in Figure 5. In Figures 5A,B, I assume that
462 all existing natural immunity is towards the first viral variant, with the second viral variant being
463 a very recent introduction. As expected, increasing overall rates of immunity to viral variant 1 at
464 the start of the simulation decreases both total deaths and peak infection rates. Because, however,
465 the rate of decrease is similar across all vaccination strategies, the overall level of natural
466 immunity to the first viral variant has minimal impact on the choice of vaccination strategy. In
467 Figures 5C,D, I consider a scenario where 10% of the population has natural immunity, but for
468 some fraction of individuals this immunity is targeted against viral variant 1, and for others it is
469 targeted against viral variant 2. Unlike changes in the overall levels of immunity, changes in the



470

471 **Fig. 4** (A,C) Total number of deaths and (B,D) peak infections as a function of (A,B) the initial
 472 fraction of the population with natural immunity to viral variant 1 and assuming no immunity to
 473 viral variant 2 or (C,D) and the fraction of naturally immune individuals protected against viral
 474 variant 2, assuming an overall level of natural immunity of 10%. All parameters and initial
 475 conditions except initial fractions of naturally immune individuals are as shown in Table 1.
 476 Results shown are median values over 30 trials.

477

478

479 relative fraction of the population that is protected against each viral variant does impact

480 performance of the different vaccinations strategies differently. In particular, when more of the

481 population is already immune to viral variant 1, it accentuates the benefit of vaccinating against

482 viral variant 2 and vice versa. This is because, when ~10% of the population has natural

483 immunity to viral variant 1(2), vaccinating against this variant means that ~10% of vaccines are

484 ‘wasted’. With decreasing levels of natural immunity against viral variant 1(2), however, the

485 number of wasted variant 1(2) vaccines decreases. Interestingly, despite the loss of ‘wasted’
486 vaccines, vaccinating against the faster spreading second variant is still the better option for
487 preventing deaths, and remains comparable for lowering peak infection rates even when all
488 existing natural immunity is targeted against this strain. This shows how viral transmissibility
489 swamps most other considerations when determining the optimal vaccine target. Notably,
490 however, for all scenarios shown in Figure 5, vaccination against the second variant and the
491 mixed vaccination strategy are comparable, suggesting that a mixed strategy can perform as well
492 or almost as well as specifically targeting the fast-spreading strain (but see Figure 2).

493

494 **Discussion**

495 In this paper, I use a stochastic simulation to examine how the choice of vaccine target
496 impacts outcomes of an outbreak of COVID-19 consisting of two different viral variants and for
497 which vaccine cross-protection is incomplete (though not necessarily zero). Although inspired by
498 the recent emergence of the B.1.1.7 COVID-19 strain in the United Kingdom, predictions from
499 this model are not restricted to any particular viral variant. Rather, model predictions hold for
500 any virus strain that emerges and that exhibits a higher R_0 than the dominant circulating strain – a
501 typical trajectory for virus evolution. Indeed, as I write this paper, it is becoming clear that a
502 second more transmissible COVID-19 strain has emerged in South Africa²³. Like the UK B.1.1.7
503 strain, the South African variant has the N501Y mutation, although it is otherwise quite different.

504 As with increased transmission, viral variants that ‘escape’ current antibody responses are
505 also anticipated as a common trajectory of viral evolution. Although many scientists are hopeful
506 that existing vaccines will provide strong cross-protection against the B.1.1.7 viral variant from
507 Southern England, the South African variant appears to have even more mutations in the spike

508 protein. This reduces the likelihood that current vaccines will be able to neutralize it²⁴. And even
509 if current vaccines are largely effective against both the South England and South African viral
510 variants, as more and more of the global population becomes immune to current circulating
511 COVID-19 strains – either through natural infection or via vaccination – the selective pressures
512 favoring escape mutants will increase. Thus, it is almost inevitable that fast-spreading variants
513 that are not well-covered by existing vaccines will emerge during the course of vaccine roll-out
514 across the globe.

515 One benefit of the technologies being used to develop COVID-19 vaccines and, in
516 particular, of the mRNA vaccine approach, is the ease with which different viral variants can be
517 exchanged during vaccine development and production. However, because mRNA vaccine
518 technologies are relatively new, and have not been systematically tested in human populations
519 prior to the COVID-19 pandemic, it is not clear whether *multiple* different viral targets can be
520 included simultaneously (i.e., multivalent vaccines). Consequently, I sought to address the
521 question of which viral variant to target in the event that a vaccine can only be produced against
522 a single variant (monovalent) but there are multiple variants circulating.

523 Very broadly, my analysis suggests that it is almost always better to develop vaccines
524 that target the faster spreading viral variant. This is true even when the slower spreading variant
525 is 100- to 1000-fold more prevalent at the onset of the vaccination period and even when cross-
526 protection is relatively high. This outcome is a direct result of the nature of exponential growth.
527 In particular, exponential growth rapidly accentuates even slight differences in populations with
528 different exponential growth rates (or different R_0 values, in the case of diseases). As a
529 consequence, over a matter of days to months, any initial advantage of the more prevalent but
530 slower spreading viral variant is rapidly swamped by the diverging trajectories of the viral

531 growth curves. Surprisingly, while targeting the slow spreading variant is rarely beneficial, a
532 mixed strategy, where 50% of the population receives a vaccine against one strain, and 50%
533 receives a vaccine against the other strain, can perform relatively well, at least when the
534 differences in viral transmission rates are not extreme (e.g. the second viral variant is $\leq 50\%$ more
535 transmissible than the first). That said, for more extreme differences in transmission rates, the
536 mixed strategy rapidly loses traction, and vaccination against the fast-spreading viral variant can
537 save numerous lives, as well as lower peak infection rates, even relative to the mixed strategy.

538 While most realistic scenarios that I consider suggest that it is best to develop vaccines
539 against the faster-spreading viral variant, this is not universally true. Factors that promote the
540 viability of vaccination against the slow-spreading variant include smaller differences in growth
541 rates between the two viral strains (see Figure 2), as well as faster vaccine roll-outs that leave
542 less time for the fast-spreading virus to overcome its initial lower prevalence (see Figure 3). In
543 addition, vaccination against the slow spreading viral variant is better when a larger relative
544 fraction of the population is already immune to the fast spreading viral variant, when a larger
545 relative fraction of the population is infected with the slow spreading viral variant, and when
546 cross-protection is more complete. Thus, it is not inconceivable that there would be locations
547 where vaccination against the slow spreading strain is preferable. Depending on how many
548 people in Southern England have already been infected with B.1.1.7, for example, it may be
549 more prudent to vaccinate against the original strain. Nevertheless, this appears to be the
550 exception, rather than the rule. More generally, it seems that, for a largely susceptible population,
551 and given current low rates of vaccine disbursement and delivery around the globe, it would be
552 prudent if at least some vaccine companies switched their current formulations to target the

553 newly emerged, highly transmissible COVID-19 variants that have been discovered in England
554 and South Africa.

555 Although I designed my model to capture a range of important effects that could impact
556 the benefits of different vaccination strategies, my model does make a number of simplifying
557 assumptions. First, and foremost, I do not consider the two-dose vaccination schedule that is
558 currently in use for both the Pfizer-BioNTech vaccine and the Moderna vaccine. Rather, my
559 model ignores priming and assumes that a single vaccine dose results in a person acquiring full
560 immunity. This simplifying assumption is most appropriate if the first dose of vaccine either
561 does not provide much immunity, or else provides nearly complete protection. Predictions will
562 be less accurate, however, if the first dose provides partial immunity that is then increased by the
563 second dose. Another simplifying assumption of my model is that the population is well-mixed
564 and without any structure like age-classes or differences in behavior (e.g., ability to
565 telecommute, willingness to wear masks) that might lead to differential interactions among
566 groups or else different exposure rates or susceptibilities to exposures. As well, I do not consider
567 an exposed class or waning immunity. Likewise, I do not consider differences in infectious
568 period or disease outcomes that may be garnered by immunity, either to the infecting strain or to
569 the off-target strain. In reality, though, it is likely that vaccination would, at the very least, lower
570 death rates of an infection, even if it does not fully protect against infection itself. Another
571 assumption that I make is that, other than transmission rates, both viral variants are largely
572 identical. That is, they induce similar death rates, have similar recovery rates, and illicit similar
573 degrees of cross-protection. Finally, I assume a closed population, with no new individuals or
574 infections introduced. Many of these complexities could be added to my model, though most
575 would require additional parameters which are currently unknown. Nevertheless, as more

576 information becomes available about newly emerging strains, their relative transmissibilities and
577 the degree of cross-protection, including additional model details and complexities will become
578 more feasible.

579 Overall, my model suggests that, except in very rare instances, monovalent COVID-19
580 vaccines should target the fastest-spreading strain of the virus, regardless of how prevalent that
581 strain is at the outset of the vaccination period, and regardless of the degree of cross-protection
582 offered by either vaccines or natural immunity. For scenarios where targeting the slower-
583 spreading strain is equivalent or even marginally better than targeting the faster-spreading strain,
584 total deaths and peak infection rates tend to be low for all vaccination strategies. However, for
585 scenarios where targeting the faster-spreading strain is best, differences in total deaths and peak
586 infections can be substantial. Thus, even from a precautionary principle, the safest bet is to target
587 the variant with the higher transmission rate. The mixed strategy – vaccinating half of the
588 population against each viral variant – performs nearly as well as vaccinating against the fast
589 spreading virus over a surprisingly large range of viral transmission rates. However, when the
590 fast spreading virus is significantly more transmissible than the original strain, even the mixed
591 strategy can result in a sizeable number of additional deaths as compared to vaccination solely
592 against the fast spreading strain. Thus, for example, for the low estimate that the B.1.1.7 strain is
593 50% more transmissible than its predecessor, the mixed vaccination strategy is nearly as good as
594 vaccination against B.1.1.7 alone. However, for the high estimate that the B.1.1.7 strain is 70%
595 more transmissible, the mixed strategy dramatically underperforms, leading to nearly 70% more
596 deaths as compared to a strategy where all vaccine efforts are focused on the B.1.1.7 strain.

597 New strains of COVID-19 will continue to emerge that are more transmissible than the
598 current variants, and that escape or partially escape from the current vaccines. Although we

599 cannot prevent this from happening, we can make decisions about vaccination strategies that
600 minimize the negative health outcomes of such events. Naturally, the best long-term solution will
601 be to develop multivalent mRNA vaccines that simultaneously protect against all dominant
602 COVID-19 viral variants in circulation. Until that is possible, however, my study provides ‘rule-
603 of-thumb’ guidance for public health officials and vaccine companies alike. Specifically, my
604 study suggests that, in most cases, targeting vaccines against the fastest spreading viral variant
605 will at worst perform equally well as other strategies and, at best, save many lives.

606

607 **References**

- 608 1 Cucinotta, D. & Vanelli, M. WHO declares COVID-19 a pandemic. *Acta Bio Medica:*
609 *Atenei Parmensis* **91**, 157 (2020).
- 610 2 Le, T. T., Andreadakis, Z., Kumar, A., Roman, R. G., Tollefsen, S., Saville, M. &
611 Mayhew, S. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov* **19**,
612 305-306 (2020).
- 613 3 Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M.,
614 McClung, N., Campos-Outcalt, D., Morgan, R. L. & Mbaeyi, S. The Advisory
615 Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-
616 BioNTech COVID-19 Vaccine—United States, December 2020. *Morbidity and Mortality*
617 *Weekly Report* **69**, 1922 (2020).
- 618 4 Oliver, S. E. The Advisory Committee on Immunization Practices’ Interim
619 Recommendation for Use of Moderna COVID-19 Vaccine—United States, December
620 2020. *MMWR. Morbidity and Mortality Weekly Report* **69** (2020).
- 621 5 Akpan, N. Why a coronavirus vaccine could take way longer than a year. *National*
622 *Geographic* (2020).
- 623 6 Mahase, E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk
624 and elderly people shows. *BMJ: British Medical Journal (Online)* **371** (2020).
- 625 7 Mahase, E. *BMJ* 2020;371:m4826.
- 626 8 Schlake, T., Thess, A., Fotin-Mleczek, M. & Kallen, K.-J. Developing mRNA-vaccine
627 technologies. *RNA biology* **9**, 1319-1330 (2012).
- 628 9 Jackson, L. A., Anderson, E. J., Roupahel, N. G., Roberts, P. C., Makhene, M., Coler, R.
629 N., McCullough, M. P., Chappell, J. D., Denison, M. R. & Stevens, L. J. An mRNA
630 vaccine against SARS-CoV-2—preliminary report. *New England Journal of Medicine*
631 (2020).
- 632 10 Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in
633 vaccinology. *Nature reviews Drug discovery* **17**, 261 (2018).
- 634 11 Tang, J. W., Tambyah, P. A. & Hui, D. S. Emergence of a new SARS-CoV-2 variant in
635 the UK. *Journal of Infection* (2020).

- 636 12 Kupferschmidt, K. (American Association for the Advancement of Science, 2021).
- 637 13 Santos, J. C. & Passos, G. A. The high infectivity of SARS-CoV-2 B. 1.1. 7 is associated
638 with increased interaction force between Spike-ACE2 caused by the viral N501Y
639 mutation.
- 640 14 Jackson, C. B., Zhang, L., Farzan, M. & Choe, H. Functional importance of the D614G
641 mutation in the SARS-CoV-2 spike protein. *Biochemical and Biophysical Research
642 Communications* (2020).
- 643 15 Wise, J. (British Medical Journal Publishing Group, 2020).
- 644 16 Mahase, E. (British Medical Journal Publishing Group, 2020).
- 645 17 Sano, K., Aina, A., Suzuki, T. & Hasegawa, H. The road to a more effective influenza
646 vaccine: Up to date studies and future prospects. *Vaccine* **35**, 5388-5395 (2017).
- 647 18 Vidor, E. The nature and consequences of intra-and inter-vaccine interference. *Journal of
648 comparative pathology* **137**, S62-S66 (2007).
- 649 19 Gillespie, D. T. Exact stochastic simulation of coupled chemical reactions. *The journal of
650 physical chemistry* **81**, 2340-2361 (1977).
- 651 20 Provention, C. C. f. D. C. a. *Duration of Isolation and Precautions for Adults with
652 COVID-19*, <<https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>>
653 (2020).
- 654 21 Brazeau, N., Verity, R., Jenks, S., Fu, H., Whittaker, C., Winskill, P., Dorigatti, I.,
655 Walker, P., Riley, S. & Schnekenberg, R. P. Report 34: COVID-19 infection fatality
656 ratio: estimates from seroprevalence. (2020).
- 657 22 Liu, Y., Gayle, A. A., Wilder-Smith, A. & Rocklöv, J. The reproductive number of
658 COVID-19 is higher compared to SARS coronavirus. *Journal of travel medicine* (2020).
- 659 23 Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J.,
660 Doolabh, D., Pillay, S., San, E. J. & Msomi, N. Emergence and rapid spread of a new
661 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with
662 multiple spike mutations in South Africa. *medRxiv* (2020).
- 663 24 Staff, R. *UK Scientists worried vaccines may not work on S. African coronavirus variant*,
664 <[https://www.reuters.com/article/uk-health-coronavirus-britain-south-afri/
665 worried-vaccines-may-not-work-on-safrican-coronavirus-variant-itv-idUSKBN2990T2](https://www.reuters.com/article/uk-health-coronavirus-britain-south-afri/uk-scientists-worried-vaccines-may-not-work-on-safrican-coronavirus-variant-itv-idUSKBN2990T2)>
666 (2021).
- 667